ATHX:NSD-Athersys, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.18

Change

-0.09 (-3.96)%

Market Cap

USD 0.45B

Volume

2.83M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-9.20 (-5.77%)

USD63.06B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.48 (+0.69%)

USD55.88B 20.89 14.64
REGN Regeneron Pharmaceuticals, Inc

+7.45 (+1.62%)

USD49.34B 15.09 12.06
ALXN Alexion Pharmaceuticals, Inc

-1.88 (-1.21%)

USD34.03B 56.92 34.28
RPRX Royalty Pharma plc

-1.10 (-2.29%)

USD30.02B 22.60 14.73
BGNE BeiGene, Ltd

+3.11 (+0.94%)

USD29.79B N/A N/A
SGEN Seagen Inc

-0.55 (-0.35%)

USD28.55B 46.76 41.48
BNTX BioNTech SE

-2.63 (-2.29%)

USD27.59B -99,999.99 N/A
GMAB Genmab A/S

-1.55 (-4.05%)

USD25.02B 26.59 2.93
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ATHX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.57% 62% D- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.57% 62% D- 73% C
Trailing 12 Months  
Capital Gain 77.24% 68% D+ 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.24% 68% D+ 76% C
Trailing 5 Years  
Capital Gain 11.22% 49% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.22% 49% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 9.94% 51% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.94% 51% F 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 39.61% 69% D+ 36% F
Risk Adjusted Return 25.10% 55% F 51% F
Market Capitalization 0.45B 50% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.52 28% F 20% F
Price / Cash Flow Ratio -12.70 57% F 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -186.84% 13% F 5% F
Return on Invested Capital -137.04% 16% F 6% F
Return on Assets -71.37% 7% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 10.74 12% F 6% F
Short Percent 13.64% 17% F 14% F
Beta -1.49 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.